argenex SE $ARGX Shares Purchased by BNP Paribas Financial Markets

Key Points

• BNP Paribas Financial Markets significantly increased its holdings in argenex SE by acquiring 123,127 shares, raising its total to 133,359 shares, which are now valued at approximately $78.93 million.
• Institutional investors collectively own 60.32% of argenex, with notable increases in positions from firms like Rakuten Securities and Brooklyn Investment Group during the first quarter.
• argenex reported strong earnings, with an EPS of $3.74 for the quarter, exceeding analyst expectations, and it currently has a consensus rating of "Buy" from analysts.

BNP Paribas Financial Markets boosted its stake in argenex SE (NASDAQ:ARGX - Free Report) by 1,203.4% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 133,359 shares of the company's stock after acquiring an additional 123,127 shares during the quarter. BNP Paribas Financial Markets owned about 0.22% of argenex worth $78,931,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Greenleaf Trust boosted its holdings in argenex by 3.5% in the 1st quarter. Greenleaf Trust now owns 624 shares of the company's stock worth $369,000 after acquiring an additional 21 shares during the period. Rakuten Securities Inc. boosted its holdings in argenex by 56.4% in the 1st quarter. Rakuten Securities Inc. now owns 61 shares of the company's stock worth $36,000 after acquiring an additional 22 shares during the period. Sequoia Financial Advisors LLC boosted its holdings in argenex by 1.3% in the 1st quarter. Sequoia Financial Advisors LLC now owns 1,829 shares of the company's stock worth $1,083,000 after acquiring an additional 24 shares during the period. M&T Bank Corp boosted its holdings in argenex by 0.6% in the 1st quarter. M&T Bank Corp now owns 4,296 shares of the company's stock worth $2,542,000 after acquiring an additional 27 shares during the period. Finally, Nkcfo LLC boosted its stake in shares of argenex by 32.7% during the 1st quarter. Nkcfo LLC now owns 146 shares of the company's stock valued at $86,000 after buying an additional 36 shares during the last quarter. Hedge funds and other institutional investors own 60.32% of the company's stock.

argenex Price Performance

ARGX traded up $11.65 during trading hours on Thursday, hitting $733.66. 544,073 shares of the stock were exchanged, compared to its average volume of 354,959. The stock has a 50-day simple moving average of $624.07 and a 200-day simple moving average of $601.86. argenex SE has a 12 month low of $510.05 and a 12 month high of $742.52. The stock has a market cap of $44.90 billion, a price-to-earnings ratio of 37.62, a price-to-earnings-growth ratio of 0.76 and a beta of 0.41.

argenex (NASDAQ:ARGX - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The company reported $3.74 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.84 by $0.90. argenex had a return on equity of 21.06% and a net margin of 40.98%.The firm had revenue of $866.79 million for the quarter, compared to analysts' expectations of $776.82 million. Sell-side analysts expect that argenex SE will post 3.13 EPS for the current year.

Wall Street Analyst Weigh In

ARGX has been the subject of several research analyst reports. JMP Securities set a $699.00 target price on argenex in a research note on Wednesday, May 14th. Robert W. Baird upgraded argenex from a "neutral" rating to an "outperform" rating and set a $680.00 target price for the company in a research note on Tuesday, May 13th. Bank of America increased their target price on argenex from $880.00 to $887.00 and gave the company a "buy" rating in a research note on Tuesday. HC Wainwright increased their target price on argenex from $720.00 to $774.00 and gave the company a "buy" rating in a research note on Friday, August 1st. Finally, Oppenheimer increased their target price on argenex from $704.00 to $708.00 and gave the company an "outperform" rating in a research note on Friday, May 9th. Two analysts have rated the stock with a Strong Buy rating and twenty-one have assigned a Buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $772.84.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.